Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156331 | 0.88 | KDM4E (0.36) | ALDH1A1CCNE1CDK2CLK1DYRK1A | |
| SCHEMBL389548 | 0.71 | PTPN1 (0.47) | ACMSDALDH1A1CCNE1CDK2SERPINE1 | |
| SCHEMBL16408718 | 0.67 | GPR35 (0.46) | ALDH1A1GPR35DAOKDM4E | |
| Cyclohexanone SCHEMBL3244111 | 0.67 | PTPN1 (0.46) | ACMSDALDH1A1CCNE1CDK2SERPINE1 | |
| SCHEMBL1174476 | 0.67 | PTPN1 (0.48) | ACMSDALDH1A1GRM2KDM4EHPGD | |
| SCHEMBL2157243 | 0.66 | GPR35 (0.38) | ACMSDALDH1A1CCNE1CDK2GPR35 | |
| SCHEMBL394705 | 0.65 | ASH1L (0.52) | — | |
| SCHEMBL6413095 | 0.64 | KMT2A (0.44) | ACMSDALDH1A1DAOKDM4EHPGD | |
| SCHEMBL6296691 | 0.62 | DRD2 (0.60) | ALDH1A1CCNE1CDK2KDM4ELMNA | |
| Bicarbonate SCHEMBL10962051 | 0.62 | ACMSD (0.49) | ACMSDALDH1A1CLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781431-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | disclosed |
| EP-1664059-B1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-09-12 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | ACMSD 3669/4885ALDH1A1 351/4885CCNE1 1343/4885 |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ZC3HAV1, XDH, TPMT | ACMSD 3794/4885ALDH1A1 397/4885CCNE1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.